Edgewise Therapeutics Inc Total Assets
Edgewise Therapeutics Inc total assets. Based on the latest financial reports, Edgewise Therapeutics Inc (EWTX) holds total assets worth $518.52 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Edgewise Therapeutics Inc worth for the company's overall valuation and market capitalisation.
Total Assets of Edgewise Therapeutics Inc (2019–2025)
Total assets of Edgewise Therapeutics Inc from 2019 to 2025. This chart illustrates how Edgewise Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See EWTX live share price for real-time trading data and today's change.
Edgewise Therapeutics Inc - Asset Composition Analysis
Edgewise Therapeutics Inc Total Assets Breakdown (December 2025)
Edgewise Therapeutics Inc total assets breakdown as of December 2025. Edgewise Therapeutics Inc's total assets of $518.52 Million consist of 98.3% current assets and 1.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Edgewise Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Edgewise Therapeutics Inc current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Edgewise Therapeutics Inc's current assets represent 98.3% of total assets in 2025, an increase from 98.0% in 2019.
- Cash Position: Cash and equivalents constituted 11.1% of total assets in 2025, down from 96.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Edgewise Therapeutics Inc Competitors by Total Assets
Key competitors of Edgewise Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Edgewise Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 22.61 | 20.99 | 44.96 |
| Quick Ratio | 22.61 | 20.99 | 44.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $487.25 Million | $422.06 Million | $296.23 Million |
Edgewise Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Edgewise Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.70 |
| Latest Market Cap to Assets Ratio | 6.62 |
| Asset Growth Rate (YoY) | 13.5% |
| Total Assets | $552.60 Million |
| Market Capitalization | $3.66 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Edgewise Therapeutics Inc's assets at a significant premium (6.62x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Edgewise Therapeutics Inc's assets grew by 13.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Edgewise Therapeutics Inc (2019–2025)
The table below shows the annual total assets of Edgewise Therapeutics Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $552.60 Million | +13.51% |
| 2024-12-31 | $486.82 Million | +43.17% |
| 2023-12-31 | $340.04 Million | -7.37% |
| 2022-12-31 | $367.10 Million | +28.70% |
| 2021-12-31 | $285.23 Million | +117.51% |
| 2020-12-31 | $131.14 Million | +434.35% |
| 2019-12-31 | $24.54 Million | -- |
About Edgewise Therapeutics Inc
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company… Read more